photo of

Details

Role Group Leader / Senior Research Fellow
Research area Genomic Medicine

Contact

Available for student supervision
Associate Professor David Godler is a Principal Fellow at the University of Melbourne, group leader of the Diagnosis and Development Laboratory at the Murdoch Children’s Research Institute (MCRI) and is on the executive of the Genomic Screening Consortium for Australian Newborns (GenSCAN). He has completed his PhD in 2007 at the Department of Medicine, Monash University in genetics and immunology, then undertook post-doctoral studies on epigenetic disorders associated with chromosomal abnormalities and developmental delay in the laboratory of Professor Andy Choo. He was later appointed senior postdoctoral fellow at the Victorian Clinical Genetics Services (VCGS) and MCRI, demonstrating strong evidence of innovation and research translation. To date he has been named as an inventor on 6 patent families (with more than 40 patent filings), including 16 granted patents, related to technologies developed for different diagnostic and screening applications, He has 59 publications (41 as 1st or last author) in such quality journals as Genetics in Medicine (X4), Clinical Chemistry (X3), Neurology (X2), JAMA Neurology (X1), JAMA Network Open (X1) and Molecular Autism (X1). In 2018, he was awarded a Next Generation Clinical Researchers Program - Career Development Fellowship, focusing on improved diagnosis, natural history studies and clinical trials for neurodevelopmental disorders associated with intellectual disability and autism. In 2020 he established and currently leads the Australian first Chromosome 15 imprinting Disorders national biobank. In 2022 he was awarded a 5-year program funding from the Genomics Health Futures Mission, the Medical Research Future Fund. This program aims to assess benefits of extended epi-genomic newborn screening workflow developed by his group on 100,000 infants recruited into a $55 million funded whole-of-state birth cohort called Generation Victoria (https://www.genv.org.au/for-researchers/current-genv-collaborations/).
Associate Professor David Godler is a Principal Fellow at the University of Melbourne, group leader of the Diagnosis and Development Laboratory at the Murdoch Children’s Research Institute (MCRI) and is on the executive of the Genomic Screening...
Associate Professor David Godler is a Principal Fellow at the University of Melbourne, group leader of the Diagnosis and Development Laboratory at the Murdoch Children’s Research Institute (MCRI) and is on the executive of the Genomic Screening Consortium for Australian Newborns (GenSCAN). He has completed his PhD in 2007 at the Department of Medicine, Monash University in genetics and immunology, then undertook post-doctoral studies on epigenetic disorders associated with chromosomal abnormalities and developmental delay in the laboratory of Professor Andy Choo. He was later appointed senior postdoctoral fellow at the Victorian Clinical Genetics Services (VCGS) and MCRI, demonstrating strong evidence of innovation and research translation. To date he has been named as an inventor on 6 patent families (with more than 40 patent filings), including 16 granted patents, related to technologies developed for different diagnostic and screening applications, He has 59 publications (41 as 1st or last author) in such quality journals as Genetics in Medicine (X4), Clinical Chemistry (X3), Neurology (X2), JAMA Neurology (X1), JAMA Network Open (X1) and Molecular Autism (X1). In 2018, he was awarded a Next Generation Clinical Researchers Program - Career Development Fellowship, focusing on improved diagnosis, natural history studies and clinical trials for neurodevelopmental disorders associated with intellectual disability and autism. In 2020 he established and currently leads the Australian first Chromosome 15 imprinting Disorders national biobank. In 2022 he was awarded a 5-year program funding from the Genomics Health Futures Mission, the Medical Research Future Fund. This program aims to assess benefits of extended epi-genomic newborn screening workflow developed by his group on 100,000 infants recruited into a $55 million funded whole-of-state birth cohort called Generation Victoria (https://www.genv.org.au/for-researchers/current-genv-collaborations/).

Top Publications

  • Godler, DE, Butler, MG. Special Issue: Genetics of Prader–Willi Syndrome. Genes 12(9) : 1429 2024
    view publication
  • Kraan, C, Date, P, Baker, E, Rattray, A, Sanguex, M, Amor, D, Godler, D. Wearable digital gait-based outcome measures for children with Fragile X, Prader-Willi and Angelman syndromes. 2024
    view publication
  • Kraan, C, Date, P, Baker, E, Rattray, A, Sanguex, M, Amor, D, Godler, D. Wearable gait outcome measures for children with Angelman syndrome. 2024
    view publication
  • Kraan, C, Date, P, Baker, E, Rattray, A, Sanguex, M, Amor, D, Godler, D. Digital gait-analysis based biomarkers for natural history studies and clinical trials with children who have Prader-Willi syndrome. 2024
    view publication
  • Kraan, C, Baker, E, Arpone, M, Bui, M, Ling, L, Amor, D, Godler, D. Epigenetic DNA methylation biomarkers and the “target gene” approach. 2024
    view publication

Page 4 of 15